Abstract B16: Verteporfin synergizes antitumoral effect of anti-PD-1 in mice cholangiocarcinoma models


 Cholangiocarcinoma (CCA) is a heterogenous cancer originated from the biliary epithelium in the biliary tree system. The incidence of CCA has gradually increased across nation/worldwide and overall prognosis is poor with only 10% of 5-year survival rate. Recently developed immune checkpoint inhibitor-based immunotherapy has less benefit on CCA patients. We investigated antitumoral effect of verteporfin in combination of anti-PD-1 in YAP/Akt and Notch/Akt hydrodynamic injected mouse model. Our result showed reduced liver weight in verteporfin treated mice group compared to vehicle treated mice group, both in anti-PD-1 and isotype control groups. Single cell RNA sequence showed there is reduced expression of stemness related cells from data observed in verteporfin treated group. B cell, CD8+ T cell, TAM M1 populations were increased in verteporfin treatment group and similar pattern was observed in anti-PD1 treated verteporfin group. In conclusion, verteporfin reduced tumorigenesis in CCA via control of cancer stemness in CCA animal models with anti-PD-1 immunotherapy.
 Citation Format: Jihye Lee, Jing Bian, Xin Wang, Meggie Cam, Changqing Xie. Verteporfin synergizes antitumoral effect of anti-PD-1 in mice cholangiocarcinoma models [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl):Abstract nr B16.